Ravi K Anchoori

Title: Innovations by Ravi K Anchoori

Introduction

Ravi K Anchoori is an accomplished inventor based in Elkridge, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of novel compounds. With a total of 3 patents, Anchoori's work focuses on creating effective therapies for various types of cancer.

Latest Patents

Anchoori's latest patents include groundbreaking inventions such as anti-cancer spirocyclic-guanidine compounds and bis-benzylidine piperidone proteasome inhibitors. The spirocyclic guanidine compounds are designed for use in methods of treating cancer, showcasing their potential in oncology. The bis-benzylidine piperidone, known as RA190, has demonstrated anticancer activity by covalently binding to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle. This binding inhibits proteasome function, leading to the rapid accumulation of polyubiquitinated proteins. RA190 has shown effectiveness against multiple myeloma lines, even those resistant to bortezomib, and has the potential to stabilize targets of the human papillomavirus (HPV) E6 oncoprotein, preferentially killing HPV-transformed cells.

Career Highlights

Ravi K Anchoori is affiliated with The Johns Hopkins University, where he continues to advance his research in cancer therapies. His work has contributed to the development of new orally-available proteasome inhibitors, particularly effective against multiple myeloma, cervical, and ovarian cancers.

Collaborations

Anchoori has collaborated with notable colleagues, including Richard B Roden and Balasubramanyam Karanam, to further enhance the impact of his research in the field of cancer treatment.

Conclusion

Ravi K Anchoori's innovative work in developing new cancer therapies highlights his commitment to improving patient outcomes. His contributions to the field are paving the way for more effective treatments and showcasing the importance of research in combating cancer.